Chronic hepatitis C (CHC) patients with cirrhosis may be at risk of hepatic decompensation and death when treated with alpha interferons, including PEGASYS.

合并硬化的慢性丙（CHC）患者接受α干扰素包括派罗欣治疗时存能失偿和险。

Moreover presence of insulin resistance and diabetes are risk factors for fibrosis progression and nonresponse to antiviral therapy in chronic hepatitis C (CHC).

此外，胰岛素抵抗和糖尿病是慢性丙型炎（CHC）中纤维化进展以及对抗病毒治疗无应答的危险因素。